NHS Branded Medicines Tranche Framework for London and South of England
Estimated value
£381.0m
Awarded value
£381.0m
Suppliers
1
Lots
1
Published
20 Aug 2024
Description
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
Scope
- Reference
- CF-2545400D0O000000rwimUAA
- Total value
- £380,950,720 excluding VAT
- Commercial tool
- Standalone contract
- Contract dates
- 31 Aug 2024 to 30 Aug 2026
- CPV classifications
- 33600000
- Particular suitability
- Small and medium-sized enterprises (SME)
Submission & procedure
- Submission deadline
- 05 Apr 2024, 12:00 pm
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£381.0m
Award date
21 Jul 2024
Contract start
31 Aug 2024
Contract end
30 Aug 2026